Investment further strengthens Merck's "Big 3," the key drivers for increasing Group sales to approximately € 25 billion by 2025
India is an example in front of the world to contribute towards strengthening Points of Entry during a public health emergency
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
_256_384.png)
Researchers from Bar-Ilan University find that even in old age, feeling young can lower the risks of developing physical disability and morbidity
The objective of this Phase 1 study is to determine the safety and tolerability of OLX10212 in patients with advanced AMD at multiple sites in the US.
H Clinical is the leader in decentralized clinical trial support and home visits in Latin America
We must try to make the health care system more accessible for people with disabilities
Bringing next-gen cannabinoid therapeutics to cancer patients
Site has a capital investment program of ~$30 million spent or committed over the last three years to expand capabilities and improve operational efficiencies
The new program includes upstream and downstream process development and large-scale GMP production.
Subscribe To Our Newsletter & Stay Updated
